The management of neovascular age-related macular degeneration: A systematic literature review of patient-reported outcomes, patient mental health and caregiver burden

Gale R. P., Finger R. P., Eldem B., Aslam T., Barratt J., Daien V., ...Daha Fazla

ACTA OPHTHALMOLOGICA, cilt.101, sa.1, 2023 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 101 Sayı: 1
  • Basım Tarihi: 2023
  • Doi Numarası: 10.1111/aos.15201
  • Dergi Adı: ACTA OPHTHALMOLOGICA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, L'Année philologique, BIOSIS, EMBASE, MEDLINE
  • Anahtar Kelimeler: intravitreal injections, mental health, neovascular age-related macular degeneration, patient care, quality of life, QUALITY-OF-LIFE, GROWTH-FACTOR TREATMENT, ANTI-VEGF TREATMENT, RANIBIZUMAB TREATMENT, INTRAVITREAL INJECTION, CLINICAL-TRIAL, VISION, EXPERIENCE, DEPRESSION, THERAPY
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Purpose The aim of this systematic literature review was to describe patient-reported outcomes, mental health and caregiver burden in patients with neovascular age-related macular degeneration (nAMD) treated with anti-vascular endothelial growth factor (VEGF) agents in routine clinical practice. Methods Electronic searches were conducted in Embase and MEDLINE according to pre-defined criteria. Results Of 856 records identified, 63 met inclusion criteria. Depression or depressive symptoms were reported in up to 42% of patients with nAMD. Of 25/63 (40%) studies evaluating quality of life (QoL) and using various tools, eight studies reported composite National Eye Institute Visual Functioning Questionnaire scores following anti-VEGF treatment. Of these, seven reported a statistically significant improvement at the earliest time point measured (Month 3-12) and approximately 50% reported sustained QoL benefits at 12 months. In studies comparing the attributed or different regimens, the most important factor from the patient's perspective was the likelihood that a particular regimen would maintain vision. There was a preference towards treat and extend, which was associated with a perceived reduction in patient and caregiver burden, compared to fixed dosing. Conclusions A coordinated holistic approach to patient care is key to optimizing patient well-being as well as visual outcomes. Further research regarding the patient-reported impact of nAMD management outside the trial setting (particularly international longitudinal studies) is warranted. Standardization of QoL studies would assist in establishing whether sustained QoL improvement, rather than prevention of QoL decline, should be a realistic expectation of treatment of nAMD in the longer term.